[SCHEDULE 13D/A] REVIVA PHARMACEUTICALS HOLDINGS, INC. SEC Filing

Rhea-AI Filing Summary

Dr. Laxminarayan Bhat amended his Schedule 13D to report beneficial ownership of 3,680,874 shares of Reviva Pharmaceuticals Holdings, Inc. common stock, representing approximately 3.8% of the outstanding shares based on 96,337,119 shares outstanding as of September 22, 2025. Of those shares, Dr. Bhat has sole voting and dispositive power over 3,352,177 shares, which includes 2,478,856 shares held outright and 873,321 options exercisable within 60 days. An additional 328,697 shares are shared with his spouse, primarily through options exercisable within 60 days. The filing notes Dr. Bhat ceased to be a beneficial owner of more than 5% as of September 22, 2025 and reported no transactions in the prior 60 days.

Positive

• Disclosure clarity: Filing provides a detailed breakdown of sole and shared voting/dispositive power and option exercisability.
• Regulatory update: Reporting Person accurately reports falling below the 5% threshold, ending certain Rule 13d-1 obligations.

Negative

• None.

Insights

Securities Analyst

TL;DR: Beneficial ownership fell below 5%, reducing regulatory obligations and signaling a smaller passive stake.

Dr. Bhat reports holding 3,680,874 shares (3.8%), with 3,352,177 shares under his sole control including exercisable options. The filing is a routine amendment to prior Schedule 13D filings and discloses that he did not transact in the prior 60 days. For investors, the key fact is the drop below the 5% reporting threshold, which ends certain Rule 13d-1 filing obligations and may alter perceived influence over corporate decisions.

Corporate Governance Expert

TL;DR: Ownership disclosure updated; loss of >5% status reduces activist signaling and formal filing duties.

The amendment clarifies voting and dispositive breakdowns, distinguishing between vested exercisable options and unvested options excluded from the beneficial total. The presence of shared holdings with a spouse is properly disclosed. This is a governance-relevant update but does not show new transactions or shifts in control; it primarily adjusts regulatory status.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 6)

REVIVA PHARMACEUTICALS HOLDINGS, INC.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

76152G100

(CUSIP Number)

Laxminarayan Bhat
10080 N. Wolfe Rd., Suite SW3-200,
Cupertino, CA, 95014
408-501-8881

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

09/22/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 76152G100

1

Name of reporting person

Bhat Laxminarayan

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 3,352,177.00
8	Shared Voting Power 328,697.00
9	Sole Dispositive Power 3,352,177.00
10	Shared Dispositive Power 328,697.00

11

Aggregate amount beneficially owned by each reporting person

3,680,874.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

3.8 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

See Item 5 for additional information.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.0001 per share
(b)	Name of Issuer: REVIVA PHARMACEUTICALS HOLDINGS, INC.
(c)	Address of Issuer's Principal Executive Offices: 10080 N. WOLFE ROAD, SUITE SW3-200, CUPERTINO, CALIFORNIA , 95014.
Item 1 Comment: This Amendment No. 6 (this Amendment) amends and supplements the Schedule 13D filed on December 21, 2020, as amended and supplemented by Amendment No. 1 filed on May 5, 2023, Amendment No. 2 filed on February 16, 2024, Amendment No. 3 filed on August 23, 2024, Amendment No. 4 filed on December 20, 2024 and Amendment No. 5 filed on July 1, 2025 (the Schedule 13D), by Dr. Laxminarayan Bhat (the Reporting Person) relating to the common stock, par value $0.0001 per share (Common Stock), of Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the Issuer). Capitalized terms used but not defined in this Amendment have the respective meanings ascribed to such terms in the Schedule 13D. All references in the Schedule 13D and this Amendment to the Schedule 13D shall be deemed to refer to the Schedule 13D as amended and supplemented by this Amendment.
Item 5.	Interest in Securities of the Issuer
(a)	As of the filing date of this Amendment (the Filing Date), for purposes of Rule 13d-3 promulgated under the Act, the Reporting Person is the beneficial owner of an aggregate of 3,680,874 shares of Common Stock, which represents approximately 3.8% of the outstanding shares of Common Stock, based on 96,337,119 shares of Common Stock outstanding as of September 22, 2025, as reported directly by the Issuer to the Reporting Person.
(b)	Of the 3,680,874 shares of Common Stock reported as beneficially owned by the Reporting Person herein, for purposes of Rule 13d-3 under the Act, the Reporting Person: (A) has sole voting power and dispositive power with respect to an aggregate of 3,352,177 of such shares, consisting of (i) 2,478,856 shares of Common Stock held by the Reporting Person, and (ii) 873,321 shares of Common Stock issuable upon the exercise of options held by the Reporting Person that are exercisable or will be exercisable within 60 days of the Filing Date; and (B) may be deemed to share voting power and dispositive power with respect to an aggregate of 328,697 of such shares, consisting of (i) 5,388 shares of Common Stock held by the Reporting Person's spouse, and (ii) 323,309 shares of Common Stock issuable upon the exercise of options held by the Reporting Person's spouse that are exercisable or will be exercisable within 60 days of the Filing Date. The amount of shares reported as beneficially owned by the Reporting Person excludes (i) 247,130 shares of Common Stock underlying unvested options held by the Reporting Person and (ii) 86,034 shares of Common Stock underlying unvested options held by the Reporting Person's spouse, in each case that are not exercisable within 60 days of the Filing Date.
(c)	The Reporting Person has not effected any transactions in the Common Stock or securities convertible into, exercisable for or exchangeable for, shares of Common Stock during the period commencing 60 days prior to the Filing Date.
(d)	Except as otherwise reported herein, no person or entity other than the Reporting Person has the right to receive, or the power to direct the receipt of dividends from, or the proceeds from the sale of the shares of the Common Stock reported on this Schedule 13D.
(e)	On September 22, 2025, based on the number of shares of Common Stock outstanding as of such date as described in Item 5(a) of this Amendment, the Reporting Person ceased to be the beneficial owner of more than five percent of the Common Stock and is no longer subject to the reporting requirements of Rule 13d-1(a) promulgated under the Act.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Bhat Laxminarayan

Signature:	/s/ Laxminarayan Bhat
Name/Title:	Laxminarayan Bhat
Date:	09/24/2025

FAQ

How many shares of RVPH does Laxminarayan Bhat beneficially own?

The filing states he beneficially owns 3,680,874 shares, representing approximately 3.8% of RVPH outstanding stock.

What portion of Dr. Bhat's RVPH holdings are under his sole control?

Dr. Bhat has sole voting and dispositive power over 3,352,177 shares, including 2,478,856 owned shares and 873,321 exercisable options.

Did Dr. Bhat trade RVPH shares in the 60 days before the filing?

No; the filing states he has not effected any transactions in RVPH or related securities during the 60 days prior to the filing date.

Is Dr. Bhat still a greater-than-5% beneficial owner of RVPH?

No; as of September 22, 2025, he ceased to be the beneficial owner of more than 5% and is no longer subject to Rule 13d-1(a) reporting requirements.